High-Throughput Cytochrome P450 Cocktail Inhibition Assay for Assessing Drug-Drug and Drug-Botanical Interactions

Overview

Journal Drug Metab Dispos

Specialty Pharmacology

Date 2015 Aug 20

PMID 26285764

Citations 26

Authors

Guannan Li

Ke Huang

Dejan Nikolic

Richard B van Breemen

Affiliations

Soon will be listed here.

Abstract

Detection of drug-drug interactions is essential during the early stages of drug discovery and development, and the understanding of drug-botanical interactions is important for the safe use of botanical dietary supplements. Among the different forms of drug interactions that are known, inhibition of cytochrome P450 (P450) enzymes is the most common cause of drug-drug or drug-botanical interactions. Therefore, a rapid and comprehensive mass spectrometry-based in vitro high-throughput P450 cocktail inhibition assay was developed that uses 10 substrates simultaneously against nine CYP isoforms. Including probe substrates for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and two probes targeting different binding sites of CYP3A4/5, this cocktail simultaneously assesses at least as many P450 enzymes as previous assays while remaining among the fastest due to short incubation times and rapid analysis using ultrahigh pressure liquid chromatography-tandem mass spectrometry. The method was validated using known inhibitors of each P450 enzyme and then shown to be useful not only for single-compound testing but also for the evaluation of potential drug-botanical interactions using the botanical dietary supplement licorice (Glycyrrhiza glabra) as an example.

Citing Articles

Binding characteristics of pyrrole-scaffold hepatitis B virus capsid inhibitors and identification of novel potent compounds.

Ruengsatra T, Meeprasert A, Rattanangkool E, Deesiri S, Srisa J, Udomnilobol U RSC Adv. 2023; 13(41):29004-29022.

PMID: 37807973 PMC: 10556424. DOI: 10.1039/d3ra04720b.

In vitro inhibition of human cytochrome P450 enzymes by licoisoflavone B from Glycyrrhiza uralensis Fisch. ex DC.

Chen L, Nikolic D, Li G, Liu J, van Breemen R Toxicol Sci. 2023; 196(1):16-24.

PMID: 37535691 PMC: 10613970. DOI: 10.1093/toxsci/kfad079.

Potential herb‒drug interactions between anti-COVID-19 drugs and traditional Chinese medicine.

Ye L, Fan S, Zhao P, Wu C, Liu M, Hu S Acta Pharm Sin B. 2023; .

PMID: 37360014 PMC: 10239737. DOI: 10.1016/j.apsb.2023.06.001.

Inhibitory effect of hieron on human cytochrome P450.

Lin F, Lin X, Wang X, Mei G, Chen B, Yao H Front Pharmacol. 2023; 14:1108867.

PMID: 36874034 PMC: 9975586. DOI: 10.3389/fphar.2023.1108867.

Compound Shuganjieyu Capsule on CYP450 Enzyme Activity.

Tang Y, Li Y Biomed Res Int. 2022; 2022:3228738.

PMID: 36277901 PMC: 9584658. DOI: 10.1155/2022/3228738.

References

Pelkonen O, Rautio A, Raunio H, Pasanen M . CYP2A6: a human coumarin 7-hydroxylase. Toxicology. 2000; 144(1-3):139-47. DOI: 10.1016/s0300-483x(99)00200-0. View

Shader R, Granda B, von Moltke L, Giancarlo G, Greenblatt D . Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast. Biopharm Drug Dispos. 2000; 20(8):385-8. DOI: 10.1002/1099-081x(199911)20:8<385::aid-bdd203>3.0.co;2-7. View

Dierks E, Stams K, Lim H, Cornelius G, Zhang H, Ball S . A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos. 2000; 29(1):23-9. View

Giancarlo G, Venkatakrishnan K, Granda B, von Moltke L, Greenblatt D . Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur J Clin Pharmacol. 2001; 57(1):31-6. DOI: 10.1007/s002280100268. View

Kent U, Aviram M, Rosenblat M, Hollenberg P . The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab Dispos. 2002; 30(6):709-15. DOI: 10.1124/dmd.30.6.709. View

Yuan R, Madani S, Wei X, Reynolds K, Huang S . Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos. 2002; 30(12):1311-9. DOI: 10.1124/dmd.30.12.1311. View

Testino Jr S, Patonay G . High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2002; 30(5):1459-67. DOI: 10.1016/s0731-7085(02)00480-6. View

Bertelsen K, Venkatakrishnan K, von Moltke L, Obach R, Greenblatt D . Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos. 2003; 31(3):289-93. DOI: 10.1124/dmd.31.3.289. View

Spaggiari D, Geiser L, Daali Y, Rudaz S . A cocktail approach for assessing the in vitro activity of human cytochrome P450s: an overview of current methodologies. J Pharm Biomed Anal. 2014; 101:221-37. DOI: 10.1016/j.jpba.2014.03.018. View

10.

Liu L, Han Y, Zhu J, Yu Q, Yang Q, Lu J . A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates. Biomed Chromatogr. 2014; 29(3):437-44. DOI: 10.1002/bmc.3294. View

11.

Patki K, von Moltke L, Greenblatt D . In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003; 31(7):938-44. DOI: 10.1124/dmd.31.7.938. View

12.

Chatterjee P, Franklin M . Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos. 2003; 31(11):1391-7. DOI: 10.1124/dmd.31.11.1391. View

13.

Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O . Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos. 2004; 32(6):626-31. DOI: 10.1124/dmd.32.6.626. View

14.

Walsky R, Obach R . Validated assays for human cytochrome P450 activities. Drug Metab Dispos. 2004; 32(6):647-60. DOI: 10.1124/dmd.32.6.647. View

15.

Chauret N, Gauthier A . Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos. 1998; 26(1):1-4. View

16.

Eagling V, Tjia J, Back D . Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol. 1998; 45(2):107-14. PMC: 1873357. DOI: 10.1046/j.1365-2125.1998.00679.x. View

17.

Busby Jr W, Ackermann J, Crespi C . Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos. 1999; 27(2):246-9. View

18.

Turpeinen M, Uusitalo J, Jouko U, Jalonen J, Jorma J, Pelkonen O . Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci. 2005; 24(1):123-32. DOI: 10.1016/j.ejps.2004.10.006. View

19.

Gurley B, Gardner S, Hubbard M, Williams D, Gentry W, Khan I . In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005; 77(5):415-26. PMC: 1894911. DOI: 10.1016/j.clpt.2005.01.009. View

20.

Smith D, Sadagopan N, Zientek M, Reddy A, Cohen L . Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 850(1-2):455-63. DOI: 10.1016/j.jchromb.2006.12.024. View